JP2008523098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523098A5 JP2008523098A5 JP2007545685A JP2007545685A JP2008523098A5 JP 2008523098 A5 JP2008523098 A5 JP 2008523098A5 JP 2007545685 A JP2007545685 A JP 2007545685A JP 2007545685 A JP2007545685 A JP 2007545685A JP 2008523098 A5 JP2008523098 A5 JP 2008523098A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleoside
- prodrug
- pharmaceutically acceptable
- base
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002777 nucleoside Substances 0.000 claims 42
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 41
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 21
- 239000000651 prodrug Chemical class 0.000 claims 14
- 229940002612 prodrug Drugs 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 11
- -1 cyclobutyl nucleoside Chemical class 0.000 claims 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- STRZQWQNZQMHQR-UAKXSSHOSA-N 5-fluorocytidine Chemical group C1=C(F)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 STRZQWQNZQMHQR-UAKXSSHOSA-N 0.000 claims 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 5
- 229930024421 Adenine Natural products 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 5
- 229960000643 adenine Drugs 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000004011 3 membered carbocyclic group Chemical group 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 238000000423 cell based assay Methods 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63487504P | 2004-12-10 | 2004-12-10 | |
| PCT/US2005/044709 WO2006063281A2 (en) | 2004-12-10 | 2005-12-08 | 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523098A JP2008523098A (ja) | 2008-07-03 |
| JP2008523098A5 true JP2008523098A5 (enExample) | 2009-01-29 |
Family
ID=36578634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545685A Withdrawn JP2008523098A (ja) | 2004-12-10 | 2005-12-08 | ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7495006B2 (enExample) |
| EP (1) | EP1828145A4 (enExample) |
| JP (1) | JP2008523098A (enExample) |
| CN (1) | CN101115725A (enExample) |
| AU (1) | AU2005313912A1 (enExample) |
| BR (1) | BRPI0518984A2 (enExample) |
| CA (1) | CA2590115A1 (enExample) |
| MX (1) | MX2007006961A (enExample) |
| WO (1) | WO2006063281A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8791237B2 (en) * | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| US8114414B2 (en) * | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
| US8956621B2 (en) | 1994-11-08 | 2015-02-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical dysplasia |
| US7794729B2 (en) * | 1994-11-08 | 2010-09-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for immunotherapy of cancer |
| US7820180B2 (en) * | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
| US9012141B2 (en) * | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| JP2004500405A (ja) * | 2000-03-29 | 2004-01-08 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア | 抗原の免疫原性を増強するための組成物および方法 |
| US7700344B2 (en) * | 2001-03-26 | 2010-04-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
| US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| JP2008523098A (ja) | 2004-12-10 | 2008-07-03 | エモリー・ユニバーシテイ | ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体 |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
| US8722686B2 (en) | 2008-09-19 | 2014-05-13 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| CA2899583A1 (en) | 2009-12-16 | 2011-06-23 | Pfizer Inc. | N-linked hydroxamic acid derivatives useful as antibacterial agents |
| KR101593288B1 (ko) | 2011-03-07 | 2016-02-11 | 화이자 인코포레이티드 | 항균제로서 유용한 플루오로-피리디논 유도체 |
| AU2012229218B2 (en) | 2011-03-11 | 2017-03-02 | Advaxis, Inc. | Listeria-based adjuvants |
| CN103492368A (zh) | 2011-04-08 | 2014-01-01 | 辉瑞大药厂 | 用作抗菌剂的咪唑、吡唑和噻唑衍生物 |
| AU2012238374B2 (en) | 2011-04-08 | 2015-04-02 | Pfizer Inc. | Isoxazole derivatives useful as antibacterial agents |
| PT2794628T (pt) | 2011-12-20 | 2017-07-05 | Riboscience Llc | Derivados nucleosídicos 4¿-azido-3¿-fluoro substituídos como inibidores de replicação de arn de vhc |
| PL2794629T3 (pl) | 2011-12-20 | 2018-02-28 | Riboscience Llc | 2',4'-difluoro-2'-metylo-podstawione pochodne nukleozydowe jako inhibitory replikacji rna hcv |
| US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
| JP2016519146A (ja) | 2013-05-16 | 2016-06-30 | リボサイエンス・エルエルシー | ４’−アジド，３’−デオキシ−３’−フルオロ置換ヌクレオシド誘導体 |
| NZ714927A (en) | 2013-05-16 | 2020-09-25 | Riboscience Llc | 4’-fluoro-2’-methyl substituted nucleoside derivatives |
| AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
| AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
| UA118722C2 (uk) | 2014-11-19 | 2019-02-25 | Ідорсія Фармасьютікалз Лтд | Антибактеріальні бензотіазольні похідні |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| AU2017324939B2 (en) | 2016-09-07 | 2021-10-14 | Atea Pharmaceuticals, Inc. | 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment |
| US11058704B2 (en) | 2016-10-03 | 2021-07-13 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5′-nucleotidase |
| US10519186B2 (en) | 2017-02-01 | 2019-12-31 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| TWI860279B (zh) | 2017-09-21 | 2024-11-01 | 美商里伯賽恩斯有限責任公司 | 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物 |
| KR20200140865A (ko) | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | 간경변증을 갖는 hcv 감염 환자의 치료 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN117500494A (zh) | 2021-06-17 | 2024-02-02 | 阿堤亚制药公司 | 有利的抗hcv联合疗法 |
| CN119431343A (zh) * | 2024-11-04 | 2025-02-14 | 河南大学 | 一种m6A去甲基化酶ALKBH1小分子抑制剂、合成方法及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4855466A (en) * | 1987-12-28 | 1989-08-08 | E. R. Squibb & Sons, Inc. | Purinyl cyclobutanes |
| EP0330992A3 (en) * | 1988-02-29 | 1991-11-06 | Nippon Kayaku Kabushiki Kaisha | Novel cyclobutane derivatives, processes for their preparation and pharmaceutical compositions comprising them |
| US5130462A (en) * | 1988-03-30 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Cyclobutane derivatives |
| US5185459A (en) * | 1988-03-30 | 1993-02-09 | E. R. Squibb & Sons Inc. | Bis protected (hydroxymethyl)cyclobutanols |
| US5126345A (en) * | 1988-03-30 | 1992-06-30 | E. R. Squibb & Sons, Inc. | Bis (hydroxymethyl) cyclobutyl triazolopyrimidines |
| IL92096A0 (en) * | 1988-10-25 | 1990-07-12 | Abbott Lab | Carboxylic nucleoside analogs |
| US4918075A (en) * | 1988-12-20 | 1990-04-17 | E. R. Squibb & Sons, Inc. | Purinyl and pyrimidinyl cyclobutanes and their use as antiviral agents |
| AU635642B2 (en) * | 1990-05-24 | 1993-03-25 | E.R. Squibb & Sons, Inc. | Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines |
| US5324730A (en) * | 1990-05-24 | 1994-06-28 | Nippon Kayaku Kabushiki Kaisha | Phenoxyphosphoryloxymethyl cyclobutyl purines |
| US5166397A (en) * | 1990-09-20 | 1992-11-24 | Nippon Kayaku Kabushiki Kaisha | Process for producing optically active cyclobutylamines |
| US20040229839A1 (en) * | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| JP2008523098A (ja) | 2004-12-10 | 2008-07-03 | エモリー・ユニバーシテイ | ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体 |
-
2005
- 2005-12-08 JP JP2007545685A patent/JP2008523098A/ja not_active Withdrawn
- 2005-12-08 EP EP05853591A patent/EP1828145A4/en not_active Withdrawn
- 2005-12-08 CN CNA2005800477715A patent/CN101115725A/zh active Pending
- 2005-12-08 AU AU2005313912A patent/AU2005313912A1/en not_active Abandoned
- 2005-12-08 WO PCT/US2005/044709 patent/WO2006063281A2/en not_active Ceased
- 2005-12-08 BR BRPI0518984-5A patent/BRPI0518984A2/pt not_active IP Right Cessation
- 2005-12-08 US US11/301,326 patent/US7495006B2/en active Active
- 2005-12-08 MX MX2007006961A patent/MX2007006961A/es active IP Right Grant
- 2005-12-08 CA CA002590115A patent/CA2590115A1/en not_active Abandoned
-
2009
- 2009-02-10 US US12/368,876 patent/US8114994B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008523098A5 (enExample) | ||
| JP7371931B2 (ja) | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| KR102453808B1 (ko) | 필로비리다에 바이러스 감염을 치료하는 방법 | |
| IL170894A (en) | Antiviral phosphonate analogs | |
| JP2008505902A5 (enExample) | ||
| CA2632626C (en) | Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection | |
| JP2017537158A5 (enExample) | ||
| DE69929060D1 (de) | Beta-l-2'-deoxynukleoside für die behandlung von hepatitis b virus | |
| CZ20023051A3 (cs) | Nukleosidový analog a jeho použití | |
| JP2008255121A (ja) | 抗ｂ型肝炎ウイルス活性を有するヌクレオシド | |
| JP2004513070A5 (enExample) | ||
| ZA200400925B (en) | Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | |
| JP2010510301A (ja) | 化合物 | |
| JP2004533401A5 (enExample) | ||
| WO2022174194A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| TW202233203A (zh) | 磷脂化合物及其用途 | |
| JP2001510843A5 (enExample) | ||
| JP2003532640A5 (enExample) | ||
| WO2017106710A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| JP2024038012A (ja) | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 | |
| US20190085013A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| CA3153281A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| JP2003520783A5 (enExample) | ||
| BR0314695A (pt) | Composto, processo para preparar um composto, processo para preparar um estereoisÈmero de um composto, composição para o tratamento de doenças virais, e, composição para o tratamento da hepatite b | |
| JP2005514440A5 (enExample) |